UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
UroGen Pharma Ltd. entered into a new secured term loan agreement providing up to $250,000,000 in borrowings through two tranches. A $200,000,000 Tranche A loan was funded immediately, with Tranche B of $50,000,000 available at the borrower’s election through June 30, 2027, subject to conditions.
The Tranche A proceeds refinance an existing $125,000,000 term loan and support general corporate and working capital needs; Tranche B would also fund general corporate purposes. The debt carries a fixed 8.25% annual interest rate, quarterly payments, and matures five years after the Tranche A closing date, with principal amortization beginning in the first quarter of 2030.
The facility is guaranteed by UroGen Pharma Ltd., is secured by substantially all tangible and intangible assets (including intellectual property), and includes customary affirmative and restrictive covenants but no financial covenants. Prepayments trigger a 1% exit fee and, if made within one year of each tranche’s closing, a makewhole equal to foregone interest, and a change of control requires repayment.
UroGen Pharma Ltd. director exercises RSUs into shares. On February 26, 2025, director James A. Robinson Jr. exercised 2,000 Restricted Stock Units, each representing a right to receive one ordinary share. This conversion resulted in the acquisition of 2,000 ordinary shares at a stated price of $0.00 per share.
After these transactions, his reported holdings increased to 4,000 Restricted Stock Units and 4,000 ordinary shares, all held directly. The activity reflects an equity award conversion rather than an open-market purchase or sale.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
UroGen Pharma Ltd. reported that Chief Executive Officer Elizabeth A. Barrett received a grant of 153,195 restricted stock units on January 31, 2026. Each RSU represents the right to receive one ordinary share at no purchase price. One-third of the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, aligning the CEO’s compensation with the company’s long-term performance.
The Toronto-Dominion Bank filed an amended Schedule 13G showing a passive ownership position in UroGen Pharma Ltd. as of 12/31/2025. The bank reports beneficial ownership of 2,302,334 ordinary shares, representing 4.9% of the outstanding class.
TD Bank has sole voting and dispositive power over all reported shares and no shared power. It certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of UroGen Pharma.
UroGen Pharma Ltd. General Counsel Jason Drew Smith reported equity award activity and related share sales. On January 31, 2026, multiple tranches of previously granted restricted stock units (RSUs) vested and were settled into ordinary shares, including awards originally granted in 2023, 2024, and 2025.
That same day, Smith received a new grant of 32,609 RSUs, which will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. On February 3, 2026, he sold ordinary shares at $19.69 per share to cover withholding tax obligations arising from the RSU settlements, and continued to hold tens of thousands of UroGen ordinary shares directly after these transactions.
UroGen Pharma Ltd.'s Chief Medical Officer, Mark Schoenberg, reported routine share sales linked to tax withholding on equity compensation. On February 3, 2026, he sold blocks of 1,844, 1,843, and 3,686 ordinary shares at $19.69 per share.
According to the filing, these shares were sold to satisfy withholding tax obligations arising from the settlement of restricted stock units. After these transactions, Schoenberg directly beneficially owned 144,985 ordinary shares of UroGen Pharma.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On January 31, 2026, previously granted RSUs converted into a total of 13,333 ordinary shares at an exercise price of $0, increasing his directly held ordinary shares.
On the same date, he received a new grant of 20,000 RSUs at $0. One-third of the shares underlying this new RSU award will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, providing staged future share delivery if vesting conditions are met.
UroGen Pharma Ltd. reported that its Chief Financial Officer, Chris Degnan, received a grant of restricted stock units on January 31, 2026. The award covers 32,609 RSUs, each representing a contingent right to receive one ordinary share of UroGen Pharma.
According to the grant terms, one-third of the shares underlying the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, subject to the standard conditions. Following this grant, Degnan beneficially owns 32,609 derivative securities directly.
Mark Schoenberg filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 13333 ordinary shares to be sold through Oppenheimer & Co. Inc., with an aggregate market value of 261460.13, on or about 02/02/2026 on the Nasdaq exchange.
The shares were acquired through restricted stock unit (RSU) grants from the issuer between 2023 and 2025. The notice also reports a prior sale of 10000 ordinary shares on 11/19/2025 for gross proceeds of 250005.00. By signing, the seller represents having no undisclosed material adverse information about the issuer.
UroGen Pharma Ltd. (URGN) reported an insider stock sale by its Chief Medical Officer. On 11/19/2025, the officer sold 10,000 ordinary shares in an open market transaction coded as a sale. The weighted average sale price was $25.00, with individual trades occurring between $25.00 and $25.02 per share.
The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan that was adopted on 08/15/2025. After this sale, the officer directly beneficially owned 139,025 ordinary shares of UroGen Pharma.